LEADS BIOLABS-B (09887) saw an increase of nearly 3% in late trading. At the time of writing, the stock was up 2.65%, trading at HKD 81.3, with a turnover of HKD 49.5042 million. Recently, LEADS BIOLABS-B announced that its partner, Dianthus Therapeutics (NASDAQ: DNTH), has selected Sjögren's disease (SjD), systemic lupus erythematosus (SLE), and dermatomyositis (DM) as the first three priority indications for the clinical development of LBL-047 (development code outside Greater China: DNTH212). As a core pipeline asset of strategic focus, Dianthus is advancing the clinical development of LBL-047 to validate its clinical value in these three indications with high unmet medical needs. In March 2026, Dianthus successfully completed an upsized underwritten public offering, raising approximately USD 719 million in total, providing solid capital support for the global development of LBL-047.